Application of dragon fruit branch polysaccharides in intervening in lipofuscin formation
Polysaccharides were extracted from dragon fruit branches using water extraction and prepared into medicines or food additives, solving the problems of dragon fruit branch waste and lipofuscin formation, and achieving a significant reduction in lipofuscin formation.
Patent Information
- Application Number
- CN202611150260.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-31
- Publication Date
- 2026-11-10
AI Technical Summary
Dragon fruit branches are largely discarded in large-scale cultivation, causing environmental pollution and resource waste. At the same time, existing technologies lack effective methods to reduce the production of lipofuscin, which affects the health of the skin and internal organs.
Polysaccharides were extracted from dragon fruit branches using water extraction and prepared into drugs or food additives to intervene in lipofuscin production, significantly reducing lipofuscin formation.
Dragon fruit branch polysaccharides significantly reduce lipofuscin production, providing a potential strategy for reducing age spots. The raw materials are readily available, inexpensive, and have no toxic side effects, exhibiting significant pharmacological effects.
Smart Images

Figure FT_1 
Figure FT_2
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, specifically to the application of dragon fruit branch polysaccharides in intervening in lipofuscin production. Background Technology
[0002] Lipofuscin, also known as senile pigment, is a yellowish-brown, irregularly shaped body deposited in aging cells of tissues such as nerves, myocardium, and liver. Its contents include substances with varying electron densities, lipid droplets, and vesicles. It is a residue formed from substances that cannot be digested after lysosomal action.
[0003] The effects of lipofuscin deposition on the body are mainly manifested in the skin and internal organs. On the skin, lipofuscin deposits on the skin surface to form age spots, a specific type of age-related pigmentary skin disease. This is an important marker of aging and a significant characteristic of skin aging, severely affecting facial aesthetics. Its formation is influenced by various factors, including aging, long-term ultraviolet radiation, genetic factors, chronic diseases (such as abnormal liver and kidney function), and the use of photosensitizing drugs (such as tetracycline antibiotics). Besides the skin, lipofuscin can also deposit in internal organs such as the myocardium and liver. Accumulation in brain cells increases with age; lipofuscin can be seen in pyramidal cells of the brain. In pathological conditions (such as neuronal ceroid lipofuscin deposition disease), the lipofuscin, with its yellow autofluorescence properties, is deposited in nerve cells and other cells, leading to the loss of nerve cells, primarily in the cerebral cortex and retina. In tissues such as the ovaries, the accumulation of lipofuscin aggregates is also considered a marker of cellular aging.
[0004] Some theories suggest that free radicals, especially reactive oxygen species (ROS), can lead to oxidative stress, cell damage, lipid peroxidation, and the production of lipofuscin, thus accelerating aging. Taking vitamin E and vitamin C can effectively prevent age spots caused by the oxidation of lipofuscin pigment and are recognized as anti-aging agents. Studies have shown that taking 100 IU of vitamin E and 300-500 mg of vitamin C daily for two years can significantly slow the development of atherosclerotic plaques and age spots.
[0005] *C. elegans* is a multicellular model organism whose somatic developmental lineage has been clearly studied. *C. elegans* was the first animal whose genome was fully sequenced; of its 20,000 genes, approximately 15%–30% are essential. About 40% of genes associated with human diseases are phylogenetically identical to those in *C. elegans*. Therefore, the biological information obtained from studying *C. elegans* is equally applicable to humans and higher animals. Furthermore, due to its short lifespan (approximately 3 weeks), ease of observation, highly conserved genetic information, and the visualization advantages of fluorescently labeled organs, *C. elegans* is an ideal model for drug screening.
[0006] In large-scale and standardized dragon fruit cultivation, continuous pruning is necessary to improve fruit quality and yield. A large number of branches are also generated after fruit harvesting, with approximately 60 tons of branches produced per hectare of dragon fruit plantation. However, these branches are currently not fully utilized and are mostly disposed of as waste. This not only causes secondary pollution to the dragon fruit orchard environment but also leads to a significant waste of plant resources.
[0007] Through research, the inventors have discovered that dragon fruit branch polysaccharides possess numerous health-beneficial activities. Therefore, dragon fruit branch polysaccharides have the potential for application in functional foods, food additives, daily chemical products, and pharmaceuticals. Fully researching and utilizing this waste resource of dragon fruit branches, and strengthening the comprehensive development of dragon fruit branches to produce high-value-added products, is of great significance for protecting the environment, reducing resource waste, and improving the economic benefits of the dragon fruit industry. Summary of the Invention
[0008] To address the aforementioned problems, this invention provides an application of dragon fruit branch polysaccharide in the preparation of products for intervening in lipofuscin formation. This dragon fruit branch polysaccharide is an extract obtained from dragon fruit branches by water extraction, which can significantly reduce lipofuscin formation, providing a potentially feasible strategy for reducing the formation of age spots.
[0009] This invention provides an application of dragon fruit branch polysaccharide in the preparation of products for intervening in lipofuscin formation.
[0010] In one embodiment, the dragon fruit branch polysaccharide is an extract obtained by water extraction.
[0011] In one embodiment, the dragon fruit branch polysaccharide is a freeze-dried polysaccharide powder obtained by water extraction of dragon fruit branches.
[0012] In one embodiment, the water extraction method includes the following steps: soaking dragon fruit branches in a solvent, removing the solvent to obtain pretreated dragon fruit branches, adding water, extracting under high temperature and pressure, taking the supernatant, concentrating to obtain a concentrated solution, adding ethanol, precipitating with alcohol, centrifuging, taking the precipitate, dissolving, removing impurities, dialysis, and freeze-drying to obtain the extract.
[0013] In one embodiment, the product is a drug.
[0014] In one embodiment, the drug further includes pharmaceutically acceptable excipients. In one embodiment, the dosage form of the drug includes an injectable formulation or an oral formulation.
[0015] In one embodiment, the oral formulation includes tablets, capsules, powders, pellets, or oral liquid formulations.
[0016] In one embodiment, the working concentration of dragon fruit branch polysaccharide in the application is 20 μg / mL to 80 μg / mL.
[0017] The working concentration is the concentration at which the above-mentioned components can achieve the expected effect when used. It is understood that those skilled in the art can prepare a stock solution or stock solution with a higher concentration when preparing the above-mentioned drugs, and then dilute it when used. The stock solution or stock solution and its concentration are both within the protection scope of this invention.
[0018] The present invention also provides a product for inhibiting the formation of lipofuscin, the product comprising an active ingredient, the active ingredient being dragon fruit branch polysaccharide in the application described above.
[0019] In one embodiment, the product is a drug.
[0020] In one embodiment, the drug further includes pharmaceutically acceptable excipients.
[0021] In one embodiment, the excipients include at least one of excipients, lubricants, antioxidants, preservatives, binders, fillers, or thickeners.
[0022] Compared with the prior art, the present invention has the following beneficial effects: This invention relates to the application of dragon fruit branch polysaccharide in intervening in lipofuscin formation. This dragon fruit branch polysaccharide, obtained by water extraction from dragon fruit branches, significantly reduces lipofuscin formation, providing a potentially feasible strategy for reducing age spots. Derived from dragon fruit branches, a waste product, this polysaccharide is readily available, inexpensive, and has no toxic side effects, making it safe for long-term use. The polysaccharide exhibits significant pharmacological effects, effectively reducing lipofuscin formation independently of oxidative stress, thus demonstrating feasibility in reducing lipofuscin production and possessing significant value for developing related products to reduce age spots. Attached Figure Description
[0023] Figure 1 The graph shows the effects of different doses of dragon fruit branch polysaccharide on the fluorescence intensity (left) and relative lipofuscin content (right) of lipofuscin accumulation in *C. elegans*. The graph also compares the different dose groups of dragon fruit branch polysaccharide with the negative control group. P<0.05, P<0.01, P<0.001.
[0024] Figure 2The graph shows the effect of different doses of dragon fruit branch polysaccharide on the fluorescence intensity (left) and relative ROS content (right) of reactive oxygen species (ROS) accumulation in *C. elegans*. The graph also compares the different dose groups of dragon fruit branch polysaccharide with the negative control group. P<0.05, P<0.01, P<0.001. Detailed Implementation
[0025] To facilitate understanding of the present invention, a more complete description will be given below with reference to the accompanying drawings. Preferred embodiments of the invention are shown in the drawings. However, the invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of the invention.
[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.
[0027] Unless otherwise specified, all reagents, materials, and equipment used in this embodiment are commercially available; unless otherwise specified, all test methods are conventional test methods in this field.
[0028] Example 1 Extraction of polysaccharides from dragon fruit branches.
[0029] The above-mentioned dragon fruit branch polysaccharides were extracted using a water extraction method, and the specific steps are as follows: 1. Slice red dragon fruit branches and dry them under reduced pressure until the quality is consistent; 2. The sample was extracted by soaking in petroleum ether and 95% ethanol for 4 hours to remove lipid-soluble and small molecule components such as pigments. The solvent was then evaporated to obtain the pretreated sample. 3. Accurately weigh the pretreated sample, add water at a material-to-liquid ratio of 1:20, place it in a pressure cooker extraction device, and extract at 121℃ for 30 minutes; 4. Extract the supernatant and concentrate it to 1 / 5 of the original volume. Add 5 times the volume of anhydrous ethanol and precipitate for 24 hours. Centrifuge to obtain the precipitate. 5. After dissolving the precipitate in an appropriate amount of deionized water to remove insoluble proteins, dialyze with deionized water to remove small molecule impurities, and freeze-dry to obtain polysaccharide components.
[0030] Example 2 Effects of dragon fruit branch polysaccharides on lipofuscin production in Nematode elegans.
[0031] The experiments in this embodiment were commissioned to Shanghai Southern Model Biotechnology Co., Ltd. The specific details of the experiment are as follows: 1. Nematode culture conditions.
[0032] Wild-type N2 *C. elegans* was provided by the Caenorhabditis Genetics Center (CGC) at the University of Minnesota. The nematodes were cultured on NGM (Nematode Growth Medium) solid medium containing *E. coli* OP50 at 20°C and 40–60% humidity.
[0033] 2. Sample information.
[0034] The sample "dragon fruit branch polysaccharide" was prepared according to the preparation method in Example 1, and dissolved in ddH2O. The experimental concentrations were 20 μg / mL, 40 μg / mL and 80 μg / mL.
[0035] 3. Experimental methods.
[0036] Wild-type N2 nematode eggs were synchronized and cultured for 3 days at 20℃. After developing into adults, they were transferred to 3cm culture dishes containing 2mL of NGM liquid medium per well. The medium contained an appropriate concentration of the drug, with approximately 15-20 nematodes per dish. The nematodes were cultured in the drug for 10 days, then transferred to 2% agar slides for observation under a fluorescence microscope. 5'-Fluoro-2'-deoxyuridine (FUDR) (400μM) was added to the culture medium to inhibit nematode progeny production.
[0037] 4. Statistical analysis.
[0038] The fluorescence images of lipofuscin were analyzed by relative quantification using Imgge J, and the T-test was used for comparison between the two groups.
[0039] 5. Experimental results.
[0040] like Figure 1 As shown, nematodes were cultured in samples with "dragon fruit branch polysaccharide" concentrations of 20 μg / ml and 40 μg / ml. After 10 days in liquid culture medium at 80 μg / ml, the concentration of "dragon fruit branch polysaccharide" in the sample was 20 μg / ml, and the accumulation of lipofuscin at 40 μg / ml and 80 μg / ml was significantly reduced compared with the negative control group.
[0041] Example 3 Effects of dragon fruit branch polysaccharides on reactive oxygen species (ROS) production in *Nematodeus elegans*.
[0042] The experiments in this embodiment were commissioned to Shanghai Southern Model Biotechnology Co., Ltd. The specific details of the experiment are as follows: 1. Nematode culture conditions.
[0043] Same as Example 2.
[0044] 2. Sample information.
[0045] Same as Example 2.
[0046] 3. Experimental methods.
[0047] Wild-type N2 nematode eggs were synchronized and cultured for 3 days at 20℃. After developing into adults, they were transferred to 3cm dishes containing 2mL of NGM liquid medium per well. The medium contained an appropriate concentration of the drug, with approximately 15-20 nematodes per dish. After culturing the nematodes in the drug for 10 days, the ROS difference between the drug-treated group and the negative control group was detected. After induction at 20℃ for 3 hours in M9 buffers of 5 μmol / L CM-H2DCFDA (Sigma, D6883), the nematodes were transferred to 2% agar slides for observation under a fluorescence microscope. 5'-Fluoro-2'-deoxyuridine (FUDR) (400μM) was added to the medium to inhibit nematode progeny production.
[0048] 4. Statistical analysis.
[0049] Relative quantitative analysis of ROS fluorescence images was performed using Imgge J, and the T-test was used for comparison between the two groups.
[0050] 5. Experimental results.
[0051] like Figure 2 As shown, nematodes were cultured in samples with "dragon fruit branch polysaccharide" concentrations of 20 μg / ml and 40 μg / ml. After 10 days in liquid culture medium at 80 μg / ml, and following labeling with the CM-H2DCFDA probe, the fluorescence intensity values of the "dragon fruit branch polysaccharide" samples at concentrations of 20 μg / ml, 40 μg / ml, and 80 μg / ml showed no significant difference compared to the negative control group. Although previous in vitro studies have reported that "dragon fruit branch polysaccharide" possesses antioxidant activity, our in vivo studies clearly did not reveal any antioxidant properties. Therefore, the intervention and inhibition of lipofuscin production by dragon fruit branch polysaccharide does not achieve its effect through antioxidation.
[0052] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0053] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.
Claims
1. The application of a dragon fruit branch polysaccharide in the preparation of a product for intervening in lipofuscin formation.
2. The application according to claim 1, characterized in that, The dragon fruit branch polysaccharide is an extract obtained by water extraction.
3. The application according to claim 1, characterized in that, The product is a medicine.
4. The application according to claim 3, characterized in that, The drug also includes pharmaceutically acceptable excipients.
5. The application according to claim 3, characterized in that, The dosage form of the drug includes injectable or oral formulations.
6. The application according to claim 5, characterized in that, The oral preparations include tablets, capsules, powders, pellets, or oral liquid preparations.
7. A product for inhibiting lipofuscin formation, characterized in that, The product includes an active ingredient, which is dragon fruit branch polysaccharide in any of the applications described in claims 1-6.
8. The product according to claim 7, characterized in that, The product is a medicine.
9. The product according to claim 8, characterized in that, The drug also includes pharmaceutically acceptable excipients.
10. The product according to claim 9, characterized in that, The excipients include at least one of the following: excipients, lubricants, antioxidants, preservatives, binders, fillers, or thickeners.
